Laura Harrel

Vice President

Kelly Jeng

Venture Associate

Joshua Tropper

Venture Associate

Aggie Worthington

Vice President

9 past transactions

finalsClub

Pre Seed Round in 2018
FinalsClub is an education technology company that provides applications that seek to connect students to engage in collaborative learning. They also create a platform that provides personalized help for getting through classes.

Visikol

Seed Round in 2016
Visikol Inc. is a company based in New Brunswick, New Jersey, specializing in advanced drug discovery services and bio-imaging technology. It develops and provides a range of products, including Visikol, an optical sectioning tool for plant tissues, and Visikol HISTO, a series of tissue clearing kits and reagents designed to enhance 3D imaging in tissue processing workflows. Visikol's technologies enable researchers to visualize specimens effectively, allowing for the identification of adulterants and assessment of sample quality. The company also offers comprehensive drug discovery services, including the development of 2D and 3D in vitro models, assays, and digital pathology solutions. By transforming tissues into high-resolution images and quantitative datasets, Visikol supports clients in making informed decisions during the drug discovery process. Additionally, the firm manufactures 3D immuno-labeling kits, facilitating rapid imaging of whole tissues and 3D cell culture models, thereby moving beyond traditional 2D sectioning methods.

NovoPedics

Venture Round in 2013
NovoPedics, Inc. is a U.S.-based company focused on developing innovative medical devices for patients with severe meniscal knee injuries. The company specializes in an implantable meniscus replacement and regeneration device made from a biodegradable polymer, featuring a fiber-reinforced scaffold that mimics the structure of the native meniscus. This patented design allows for total meniscal replacement and can be securely attached to both soft tissues and bones. NovoPedics aims to enhance surgical options for total meniscus replacement surgery, ultimately restoring mobility and improving the quality of life for affected patients.

Actinobac Biomed

Seed Round in 2013
Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, established in 2009. The company focuses on developing therapeutics for various medical conditions, including blood cancers, autoimmune diseases, and HIV. Its primary product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells, offering a targeted approach for treating hematologic malignancies such as leukemia and lymphoma. Additionally, research indicates that Leukotoxin may be effective against infectious diseases like HIV/AIDS and tuberculosis, as well as autoimmune conditions including rheumatoid arthritis, multiple sclerosis, and psoriasis. Actinobac Biomed is committed to advancing Leukotoxin as a protein therapeutic, while also exploring derived peptides for broader applications. The company is engaged in early-stage drug discovery in collaboration with Magellan BioScience, aiming to maintain a robust pipeline of innovative therapeutic agents.

MentiNova

Venture Round in 2013
MentiNova, Inc. is a pharmaceutical company based in Piscataway, New Jersey, established in 2012. The company focuses on developing an oral medication aimed at treating symptoms associated with Parkinson's disease, a neurodegenerative disorder. MentiNova's innovative approach seeks to enhance the quality of life for patients by providing effective treatment options for this condition and related mental health issues. Through its research and development efforts, MentiNova aims to support healthcare providers in managing the challenges posed by Parkinson's disease.

GeneAssess

Venture Round in 2012
GeneAssess, Inc. is a New Jersey-based biotechnology company that is working to validate FRY, a cancer molecular signature gene discovered by GeneAssess scientists that could provide a more accurate diagnostic biomarker for cancer staging. The FRY gene appears to be found in the breast cancer model but also shows potential for other cancers. In research performed to date, mutations in the gene increase rat susceptibility to mammary cancer and FRY reduced the growth of highly aggressive human breast cancer cells in animal models. GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, to detect genetic mutations in at-risk populations and to explore target validation for FRY. The company has an exclusive license to the intellectual property developed by Dr. Zarbl.

Affineti Biologics

Venture Round in 2011
Affineti Biologics is a New Jersey-based company that develops plaque-reducing dental hygiene products.

Actinobac Biomed

Seed Round in 2009
Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, established in 2009. The company focuses on developing therapeutics for various medical conditions, including blood cancers, autoimmune diseases, and HIV. Its primary product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells, offering a targeted approach for treating hematologic malignancies such as leukemia and lymphoma. Additionally, research indicates that Leukotoxin may be effective against infectious diseases like HIV/AIDS and tuberculosis, as well as autoimmune conditions including rheumatoid arthritis, multiple sclerosis, and psoriasis. Actinobac Biomed is committed to advancing Leukotoxin as a protein therapeutic, while also exploring derived peptides for broader applications. The company is engaged in early-stage drug discovery in collaboration with Magellan BioScience, aiming to maintain a robust pipeline of innovative therapeutic agents.

Snowdon

Venture Round in 2007
Snowdon, Inc. is a biopharmaceutical company based in Princeton, New Jersey, established in 2005. The company focuses on the discovery and development of small-molecule therapeutics targeting pain, infectious diseases, and neurological disorders. Its preclinical pipeline includes SND-121, designed for neuropathic pain, SND-159 for tuberculosis, and SND-226 for toxoplasmosis. Snowdon also explores early-stage projects for treating neurological conditions such as Fragile X Syndrome, a leading cause of autism and related behaviors. The company aims to address the significant unmet medical needs in these therapeutic areas by developing safe and effective drug candidates, which may include both new chemical entities and repurposed off-patent drugs. Notably, SND-121 has demonstrated promising safety and efficacy in rodent models, utilizing a novel mechanism of action distinct from traditional pain management therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.